PneumoWave, a digital therapeutics company based in Scotland and the U.S., has announced the appointment of digital medicine and MedTech pioneer Richie Bavasso as the new President of the organization and member of the Board of Directors.
PneumoWave today announced the closing of £7.5 m Series A financing which will enable clinical validation and regulatory submission of its biosensor technology platform
Today is Opioid Awareness Day. Our Chief Executive Officer and Founder Dr Bruce Henderson has written a powerful opinion piece based on his direct clinical experience treating patients. Learn more about the human cost of the opioid epidemic and the compassion that addicts deserve.
We are delighted to be featured in the Scotsman newspaper:
Digital health firm PneumoWave aiming to double workforce on back of £7.5m funding injection
Digital health company PneumoWave today announced the appointment of Dr Gary Cooney as Mental Health Lead, with responsibility for the planning and execution of addiction and other mental health-related treatment studies using PneumoWave’s technology platform for diagnosis and monitoring of respiratory changes.
Glasgow, February 28, 2022, Healthtech company PneumoWave today announced that Dundee University is commencing the clinical trial of its wearable device that aims to reduce the growing number of fatal opioid overdoses in Scotland.
Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the use of their monitoring platform in a clinical trial led by Professor Sir John Strang at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.
Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the commencement of a second clinical trial in partnership with the Research & Innovation Department at NHS Greater Glasgow & Clyde (NHS GG&C).
UK based Altair Medical today announced, as part of its ongoing growth story, that it is rebranding to PneumoWave. The name fully reflects the digital therapeutics platform that the company believes will transform respiratory healthcare. In a key step towards commercial launch of the platform, a multi-centre program of clinical trials is currently underway in leading academic and healthcare institutions.
UK based Altair Medical today announced it has secured £2.25m ($3.1m) of Pre-Series A funding to further develop its respiratory sensor and real-time monitoring platform. The service uses AI to detect and alert to adverse events from a range of breathing problems, with the hope of preventing a large number of early deaths.